Loading...
Market
Story
Ozempic, Wegovy Weight-Loss Drugs May Slow Ageing, Researchers Find
Aug 31, 2024, 05:28 AM
Recent scientific findings suggest that the weight-loss drug Ozempic, also known as semaglutide or Wegovy, may have the potential to slow down the biological ageing process. Researchers have hailed the drug for its 'remarkable' ability to treat the underlying causes of a range of diseases, which could extend beyond its initial use for weight loss. The drug is believed to curb the effects of ageing and has been described as offering a 'fountain of youth.' In addition to its anti-ageing potential, Ozempic is also noted for reducing the risk of death in overweight individuals with heart disease. These findings have sparked significant interest in the broader health benefits of weight-loss drugs.
View original story
Similar markets
Weight Loss • 25%
Reduced Heart Attack Risk • 25%
Improved Overall Health • 25%
Other • 25%
Mostly positive • 25%
Mixed • 25%
Mostly negative • 25%
No significant change • 25%
Ban the drugs • 25%
Issue safety warnings • 25%
No action taken • 25%
Other actions • 25%
Increased Coverage • 25%
Decreased Coverage • 25%
No Change • 25%
Other Health Risks Highlighted • 25%
Increased Sales • 25%
Decreased Sales • 25%
No Significant Change • 25%
Product Recall • 25%
Opioid overdose reduction • 25%
Alcohol intoxication reduction • 25%
Cardiovascular health improvement • 25%
Other • 25%
Significant improvement • 25%
Moderate improvement • 25%
No change • 25%
Worsening • 25%
Increase by more than 10% • 25%
Increase by 0-10% • 25%
Decrease by 0-10% • 25%
Decrease by more than 10% • 25%
Weight Reduction • 25%
Cardiovascular Risk Reduction • 25%
Improved Heart Failure Symptoms • 25%
Other • 25%
No action taken • 25%
Safety label update • 25%
Product recall • 25%
Other regulatory actions • 25%
By Novo Nordisk • 25%
By health organizations • 25%
By both • 25%
No campaigns • 25%